"Galectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multifunctional galactin initially discovered as a macrophage antigen that binds to IMMUNOGLOBULIN E, and as 29-35-kDa lectin that binds LAMININ. It is involved in a variety of biological events including interactions with galactose-containing glycoconjugates, cell proliferation, CELL DIFFERENTIATION, and APOPTOSIS.
| Descriptor ID |
D037502
|
| MeSH Number(s) |
D12.776.503.307.300
|
| Concept/Terms |
Galectin 3- Galectin 3
- CBP-30
- CBP-35
- CBP35
- Epsilon-Binding Protein
- Epsilon Binding Protein
- Galectin-3
- HL-29
- IgE Binding Protein
- Binding Protein, IgE
- Protein, IgE Binding
- IgEBP
- L-29 Lectin
- L 29 Lectin
- L-31
- L-34
- L30 Lectin
- LGALS3
- Mac-2 Antigen
- Antigen, Mac-2
- Mac 2 Antigen
- Macrophage-2 Antigen
- Antigen, Macrophage-2
- Macrophage 2 Antigen
- Carbohydrate-Binding Protein 35
- Carbohydrate Binding Protein 35
|
Below are MeSH descriptors whose meaning is more general than "Galectin 3".
Below are MeSH descriptors whose meaning is more specific than "Galectin 3".
This graph shows the total number of publications written about "Galectin 3" by people in this website by year, and whether "Galectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 3 | 2 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 4 | 0 | 4 |
| 2012 | 4 | 0 | 4 |
| 2014 | 6 | 1 | 7 |
| 2015 | 1 | 3 | 4 |
| 2016 | 6 | 0 | 6 |
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Galectin 3" by people in Profiles.
-
Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2024 Mar 19; 13(6):e031607.
-
Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Gastroenterology. 2024 Jul; 167(2):298-314.
-
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant. 2024 Mar; 59(3):334-343.
-
Targeting galectin-3 in myocardial infarction: a unique opportunity for biomarker-guided therapy. Cardiovasc Res. 2023 11 25; 119(15):2495-2496.
-
Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res. 2023 11 15; 83(22):3726-3738.
-
Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma. Cells. 2023 01 13; 12(2).
-
Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2022 05 03; 11(9):e023238.
-
Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa. 2021 Nov; 50(6):439-445.
-
Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study. Arterioscler Thromb Vasc Biol. 2020 09; 40(9):2322-2331.
-
LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine. 2019 Jun; 44:126-137.